Forum Post 41070 1965989 147430 3683158 By Anil Kumar Aruma

Forumpost 41070 1965989 147430 3683158txtby Anil Kumar Arumallasubmi

Identify and analyze the impact of medication administration errors on 3-4-year-old leukemia patients, based on a comprehensive review of relevant literature, including considerations of physical examination inadequacies, medication safety, obesity factors, medication adherence, and specific drug safety concerns.

Conduct a detailed literature review summarizing key findings from selected scholarly articles, evaluating how medication errors affect leukemia outcomes in pediatric patients. Also, describe the research methodology, including sample population, variables involved, and data collection techniques, emphasizing qualitative descriptive study methods. Conclude with implications for clinical practice and recommendations to reduce medication errors in pediatric oncology settings.

Paper For Above instruction

Introduction

Medication administration errors (MAEs) represent a significant concern in pediatric oncology, particularly among young leukemia patients aged 3-4 years. These errors can lead to adverse health outcomes, including treatment delays, disease progression, or even mortality. Recognizing the gravity of the issue, this paper conducts a comprehensive review of existing scholarly research on the impact of medication errors in this vulnerable population, aiming to identify critical factors and propose strategies for improvement.

Literature Review

Verghese et al. (2015) highlighted the inadequacies of physical examinations, which often contribute to medical errors and adverse events. This is particularly pertinent in pediatric leukemia management, where subtle clinical signs may be overlooked, leading to delayed diagnosis or inappropriate treatment. Such oversights are often not captured in traditional chart reviews but have profound implications for patient outcomes (Verghese et al., 2015).

Hockings et al. (2017) explored the impact of medication errors specifically in leukemia and stem cell transplant patients. They found that errors in medication administration exacerbate disease progression and compromise patient safety, with pediatric patients being especially susceptible due to weight-dependent dosing complexities and developmental factors. These errors can result in increased morbidity and reduce survival rates (Hockings et al., 2017).

Similarly, Douer (2016) examined the safety profile of vincristine sulfate liposome injections used in leukemia treatment, emphasizing that overdosing or incorrect administration can lead to neurotoxicity, which can be fatal. This underscores the necessity of precise dosing, especially in young children with variable body surface areas (Douer, 2016).

Obesity presents additional challenges; Tavitian et al. (2016) discussed how excess weight negatively influences the efficacy of intensive chemotherapy in leukemia patients, potentially affecting medication pharmacokinetics and increasing adverse events. Therefore, improper dosing in obese children can lead to paralysis, toxicity, or early death if not properly managed (Tavitian et al., 2016).

Medication adherence is another critical factor; Santoleri et al. (2016) demonstrated that strict adherence to tyrosine kinase inhibitors correlates with deeper molecular responses in chronic myeloid leukemia, emphasizing that errors or non-compliance can accelerate disease progression and reduce survival prospects (Santoleri et al., 2016).

Lastly, safety concerns related to chemotherapeutic agents, such as the neurotoxicity risk of vincristine, necessitate meticulous administration protocols. Mistakes in dosing, timing, or drug handling can lead to immediate life-threatening complications or long-term disabilities (Douer, 2016).

Research Methodology

This study adopts a qualitative descriptive approach, aiming to understand the impact of medication errors on pediatric leukemia patients within Harris County, Texas. The target population comprises physicians, nurses, therapists, and parents of 3-4-year-old leukemia patients. Data collection involves purposeful sampling, including interviews, surveys, and questionnaires, conducted in pediatric hospital settings.

The variables examined include the number of medication errors (dependent variable), the medication orders (independent variable), and the training level of healthcare providers (independent variable). Additional factors such as time of medication administration (e.g., during weekends or specific hours) are considered potential influencing variables. Data analysis employs descriptive statistics, coding, and narrative summaries to synthesize findings.

Implications for Clinical Practice

The review indicates that medication errors significantly threaten the health of young leukemia patients by delaying treatment, increasing toxicity risk, and reducing survival chances. To mitigate these risks, healthcare providers should implement standardized protocols, enhance staff training, and utilize technological solutions such as electronic prescribing and barcode medication administration systems. Emphasizing thorough physical assessments and dose calculations tailored to pediatric patients’ weight and surface area is crucial.

Furthermore, fostering a culture of safety, continuous professional education, and patient-family engagement can decrease error rates. Regular audits and feedback mechanisms serve as additional safeguards to improve medication safety in pediatric oncology settings.

Conclusion

Medication administration errors pose a serious threat to the health outcomes of 3-4-year-old children with leukemia. The reviewed literature underscores the importance of precise medication practices, diligent physical assessments, and individualized dosing, especially considering obesity and other complicating factors. Adopting comprehensive strategies and fostering a safety-oriented environment are essential steps toward reducing errors and enhancing the quality of leukemia care for pediatric patients.

References

  • Douer, D. (2016). Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia. The Oncologist, 21(7), 852-859.
  • Hockings, J. K., Owolabi, D. K., Broyles, J. E., & Wheelis, S. C. (2017). Impact of medication administration error on over 3 years Leukemia patients and the stimulating factors in acute leukemia and stem cell transplant patients. Supportive Care in Cancer, 25(6), 1935–1942.
  • Verghese, A., Charlton, B., Kassirer, J. P., Ramsey, M., & Ioannidis, J. P. (2015). Inadequacies of physical examination as a cause of medical errors and adverse events: a collection of vignettes. The American Journal of Medicine, 128(12), 1309–1314.
  • Tavitian, S., Denis, A., Vergez, F., Berard, E., Sarry, A., Huynh, A., & Bertoli, S. (2016). Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy. American Journal of Hematology, 91(2), 184–189.
  • Santoleri, F., Lasala, R., Ranucci, E., La Barba, G., Di Lorenzo, R., Vetrà, A., & Costantini, A. (2016). Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chronic myeloid leukemia and correlation with the depth of molecular response. Acta Haematologica, 136(1), 45–51.
  • Douer, D. (2016). Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia. The Oncologist, 21(7), 852–859.
  • Hockings, J. K., Owolabi, D. K., Broyles, J. E., & Wheelis, S. C. (2017). Impact of medication administration error on over 3 years Leukemia patients and the stimulating factors in acute leukemia and stem cell transplant patients. Supportive Care in Cancer, 25(6), 1935–1942.
  • Verghese, A., Charlton, B., Kassirer, J. P., Ramsey, M., & Ioannidis, J. P. (2015). Inadequacies of physical examination as a cause of medical errors and adverse events: a collection of vignettes. The American Journal of Medicine, 128(12), 1309–1314.
  • Tavitian, S., Denis, A., Vergez, F., Berard, E., Sarry, A., Huynh, A., & Bertoli, S. (2016). Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy. American Journal of Hematology, 91(2), 184–189.
  • Santoleri, F., Lasala, R., Ranucci, E., La Barba, G., Di Lorenzo, R., Vetrà, A., & Costantini, A. (2016). Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chronic myeloid leukemia and correlation with the depth of molecular response. Acta Haematologica, 136(1), 45–51.

Related Assignments